Christopher Ogden - 02 Feb 2026 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Chief Financial Officer
Signature
/s/ Christopher Ogden
Issuer symbol
CTMX
Transactions as of
02 Feb 2026
Net transactions value
$0
Form type
4
Filing time
04 Feb 2026, 16:23:47 UTC
Previous filing
30 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ogden Christopher Chief Financial Officer C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO /s/ Christopher Ogden 04 Feb 2026 0001914523

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +90,000 +40% $0.000000 316,271 02 Feb 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Stock Option (Right to Buy) Award $0 +325,000 $0.000000 325,000 02 Feb 2026 Common Stock 325,000 $6.09 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date.
F2 Includes 239,987 RSUs.
F3 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.